120 related articles for article (PubMed ID: 10731049)
21. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity.
Mizumura Y; Matsumura Y; Hamaguchi T; Nishiyama N; Kataoka K; Kawaguchi T; Hrushesky WJ; Moriyasu F; Kakizoe T
Jpn J Cancer Res; 2001 Mar; 92(3):328-36. PubMed ID: 11267944
[TBL] [Abstract][Full Text] [Related]
23. Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro.
Csóka K; Dhar S; Fridborg H; Larsson R; Nygren P
Cancer; 1997 Mar; 79(6):1225-33. PubMed ID: 9070502
[TBL] [Abstract][Full Text] [Related]
24. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D
J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099
[TBL] [Abstract][Full Text] [Related]
25. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
ten Tije AJ; Verweij J; Loos WJ; Sparreboom A
Clin Pharmacokinet; 2003; 42(7):665-85. PubMed ID: 12844327
[TBL] [Abstract][Full Text] [Related]
27. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
Gelderblom H; Verweij J; Nooter K; Sparreboom A
Eur J Cancer; 2001 Sep; 37(13):1590-8. PubMed ID: 11527683
[TBL] [Abstract][Full Text] [Related]
28. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN
Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Br J Clin Pharmacol; 2005 Mar; 59(3):325-34. PubMed ID: 15752379
[TBL] [Abstract][Full Text] [Related]
30. Relation between dissolution profiles and toxicity of cisplatin-loaded microspheres.
Tamura T; Imai J; Tanimoto M; Matsumoto A; Suzuki A; Horikiri Y; Suzuki T; Yoshino H
Eur J Pharm Biopharm; 2002 Mar; 53(2):241-7. PubMed ID: 11880009
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL.
Ellis AG; Webster LK
Cancer Chemother Pharmacol; 1999; 43(1):13-8. PubMed ID: 9923536
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
Hettinga JV; Lemstra W; Meijer C; Dam WA; Uges DR; Konings AW; De Vries EG; Kampinga HH
Br J Cancer; 1997; 75(12):1735-43. PubMed ID: 9192975
[TBL] [Abstract][Full Text] [Related]
33. Antigenotoxic properties of chlorophyll b against cisplatin-induced DNA damage and its relationship with distribution of platinum and magnesium in vivo.
Serpeloni JM; Batista BL; Angeli JP; Barcelos GR; Bianchi Mde L; Barbosa F; Antunes LM
J Toxicol Environ Health A; 2013; 76(6):345-53. PubMed ID: 23557233
[TBL] [Abstract][Full Text] [Related]
34. Preparation and evaluation of a novel liposomal formulation of cisplatin.
Zhou X; Wang J; Wu J; Yang X; Yung BC; Lee LJ; Lee RJ
Eur J Pharm Sci; 2015 Jan; 66():90-5. PubMed ID: 25446511
[TBL] [Abstract][Full Text] [Related]
35. Population Pharmacokinetic-Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on Nephrotoxicity.
Fukushima K; Okada A; Sasaki K; Kishimoto S; Fukushima S; Hamori M; Nishimura A; Shibata N; Shirai T; Terauchi R; Kubo T; Sugioka N
J Pharm Sci; 2016 Jan; 105(1):324-32. PubMed ID: 26852862
[TBL] [Abstract][Full Text] [Related]
36. Reduction of cisplatin toxicity and lethality by sodium malate in mice.
Ueda H; Sugiyama K; Yokota M; Matsuno K; Ezaki T
Biol Pharm Bull; 1998 Jan; 21(1):34-43. PubMed ID: 9477166
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of biosafety and intracellular uptake of Cremophor EL free paclitaxel elastic liposomal formulation.
Utreja P; Jain S; Tiwary AK
Drug Deliv; 2012 Jan; 19(1):11-20. PubMed ID: 22074176
[TBL] [Abstract][Full Text] [Related]
38. An oxovanadium(IV) complex protects murine bone marrow cells against cisplatin-induced myelotoxicity and DNA damage.
Basu A; Bhattacharjee A; Samanta A; Bhattacharya S
Drug Chem Toxicol; 2017 Jul; 40(3):359-367. PubMed ID: 27868436
[TBL] [Abstract][Full Text] [Related]
39. Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice.
Dou YN; Zheng J; Foltz WD; Weersink R; Chaudary N; Jaffray DA; Allen C
J Control Release; 2014 Mar; 178():69-78. PubMed ID: 24440663
[TBL] [Abstract][Full Text] [Related]
40. Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C.
Zhang JS; Imai T; Suenaga A; Otagiri M
Int J Pharm; 2002 Jun; 240(1-2):23-31. PubMed ID: 12062498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
